ReviewHaematologica2010
Allogeneic stem cell transplantation for acute myeloid leukemia.
Review in Haematologica, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Trial
- Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting.Experimental hematology & oncology · 2025Review
- Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation.Transplantation and cellular therapy · 2024Article
- Application of iron oxide nanoparticles in the diagnosis and treatment of leukemia.Frontiers in pharmacology · 2023Review
- Limited Contribution of Donor Characteristics to One-Year Survival After Hematopoietic Stem Cell Transplantation.Transplantation and cellular therapy · 2022Article
- Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.Annals of hematology · 2021Article
- History of drug use in allogeneic hematopoietic cell transplant recipients.Bone marrow transplantation · 2021Article
- Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia.Leukemia & lymphoma · 2020Article
- Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients.International journal of molecular sciences · 2020Article
- Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia.Journal of clinical medicine · 2019Review
- The Induction of a Permissive Environment to Promote T Cell Immune Evasion in Acute Myeloid Leukemia: The Metabolic Perspective.Frontiers in oncology · 2019Review
- Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia.Cancers · 2018Review
- Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34Frontiers in immunology · 2018Article
- Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.Bone marrow transplantation · 2017Review
- Early and Late Complications in Patients with Allogeneic Transplantation of Hematopoietic Stem Cell - Case Report.Open access Macedonian journal of medical sciences · 2017Article
- Anti-leukemic properties of deferasirox via apoptosis in murine leukemia cell lines.Blood research · 2015Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.